The medical technology company Sensodetect is publishing on Tuesday a Q&A, questions & answers, from investors, alongside an update on ongoing projects."2026 will likely be the year when commercial revenue becomes more visible, as a result of the clinical programs progressing, licensing structures for joint ventures being activated, AI development having a defined plan, and initial license payments having been confirmed," the company writes in a press release. A new screening strategy in which Sensodetect provides a complete method, AI platform, and training is currently being launched. In the first phase of the rollout, this will mainly be available to private schools and private companies, with a broader launch expected later.The company will host a live Q&A on December 15 at 12:00.